NASDAQ: $INBX Overview of Q3 2026 Financial Performance Inhibrx, a biopharmaceutical company focused on developing therapeutic candidates for various oncology and orphan diseases, has officially released its financial results for the third quarter ending September 30, 2026. The report provides transparency into the company’s ongoing research, development investments, and operational status as they continue to…